Search

Displaying results 2751 - 2760 of 4598 in total
  1. Drug

    PSN357

    go.drugbank.com/drugs/DB05044
    Experimental

    PSN357 is a glycogen phosphorylase inhibitor (GPI), which is designed to rapidly lower blood glucose levels by preventing glycogen breakdown to glucose in the liver.

  2. Drug

    Rosiglitazone

    go.drugbank.com/drugs/DB00412
    ApprovedInvestigational

    It is marketed by the pharmaceutical company GlaxoSmithKline as a stand-alone drug (Avandia) and in combination with metformin (Avandamet) or with glimepiride (Avandaryl). … Like other thiazolidinediones, the mechanism of action of rosiglitazone is by activation of the intracellular receptor class of the peroxisome proliferator-activated receptors (PPARs), specifically PPARγ

  3. Drug

    Abaloparatide

    go.drugbank.com/drugs/DB05084
    ApprovedInvestigational

    [L740] It was first approved by the FDA on April 28, 2017,[A256748] for the treatment of osteoporosis in postmenopausal women and is also used to increase bone density in men with osteoporosis. … L740] In October 2022, the EMA's Committee for Medicinal Products for Human Use (CHMP) recommended abaloparatide be granted marketing authorization in Europe [L43552] and the drug was fully authorized by

  4. Drug

    Imiglucerase

    go.drugbank.com/drugs/DB00053
    ApprovedInvestigational

    Alglucerase is prepared by modification of the oligosaccharide chains of human Beta-glucocerebrosidase.

    Products: CEREZYME 400 U/10 ML İNFÜZYONLUK KONSANTRE ÇÖZELTİ İÇİN TOZ, CEREZYME 200 U INFUZYONLUK KONSANTRE ÇÖZELTİ İÇİN TOZ İÇEREN FLAKON, 1 ADET
  5. Drug

    Ximelagatran

    go.drugbank.com/drugs/DB04898
    ApprovedWithdrawn

    Ximelagatran is an anticoagulant intended to become a replacement for warfarin by overcoming the dietary restrictions, drug interaction, and monitoring issues associated with the former.

  6. Drug

    Apixaban

    go.drugbank.com/drugs/DB06605
    ApprovedInvestigational

    Apixaban was approved by the FDA on December 28, 2012[L6043].

  7. Drug

    Halcinonide

    go.drugbank.com/drugs/DB06786
    ApprovedWithdrawn

    Halcinonide is marketed under the brand name Halog® by Ranbaxy Laboratories Inc.

  8. Drug

    Neisseria meningitidis group a capsular polysaccharide diphtheria toxoid conjugate antigen

    go.drugbank.com/drugs/DB10798
    ApprovedInvestigational

    Neisseria meningitidis group a capsular polysaccharide diphtheria toxoid conjugate antigen is an active intramuscular immunization for the prophylaxis of invasive meningococcal disease caused by *Neisseria

  9. Drug

    Tertomotide

    go.drugbank.com/drugs/DB12747
    Investigational

    It is being developed by Pharmexa A/S.

  10. Drug

    Stannsoporfin

    go.drugbank.com/drugs/DB04912
    Investigational

    Stannsoporfin is a competitive heme oxygenase (HO) inhibitor being developed by InfaCare, a subsidiary of WellSpring Pharmaceuticals, for the prevention of hyperbilirubinemia in infants at risk of developing